Screened 2026-09-04 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Doximity, Inc. holds its Accumulation at $26.35. Elevated stress, defensive posture warranted, held for 20 days.
As held on the ledger · 2026-09-04
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 20 days
Price at the screen
$26.35
Valuation
31.37 trailing · 17.01 forward price to earnings
Values screen
PASS· score 93.6
Beta
1.25
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.24%
Below 33%
Interest-bearing debt is just 0.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
16.76%
Below 33%
Cash held in interest-bearing accounts and securities is 16.8% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads STRONG OPPORTUNITY: it trades at roughly a 18% discount to our $31.04 fair value, strong competitive moat, 7.30% revenue growth.
Fair value range in USD, drawn from the 2026-09-04 screen. The gold marker is the market price at the same screen. A 17.8% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Hold. The average target sits +6% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Doctors Need Their Own Private Network Too
Every doctor in America needs a place to swap trial data and career notes without the noise of public apps. Doximity built that platform, a closed digital workspace where US physicians collaborate, read research and manage referrals in one secure spot.
This is a business with a strong moat, 30% profit margins and 19% return on equity. It trades at 13.5 times forward earnings with a 36% margin of safety to our fair value of $29.28, while the market prices it well below the growth in medical digital tools.
Risk sits around the 5% revenue growth and the street's lower $24 median target. Healthcare data rules can tighten quickly and any slowdown in doctor engagement would hit margins fast. Analysis, not advice.
DOCS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-27Markup · changed$24.94+15.9%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.9% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $30.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.5% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $25.
2026-07-18Distribution$20.59+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (20 analysts) rates it buy, with a mean price target of $25.
2026-07-03Distribution$20.59+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$20.59Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with near-perfect ethical score (94). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
